Showing results (451-460 of 794) with videos related to
Sort By:
Pageof 80
American Journal of Hematology|June 1, 2010
Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndromeTrista Stankowski-Drengler, Morie A Gertz, Jerry A Katzmann, et al.Journal of the American Society of Nephrology : JASN|April 23, 2011
Early reduction of serum-free light chains associates with renal recovery in myeloma kidneyColin A Hutchison, Paul Cockwell, Stephanie Stringer, et al.Cancer Research|January 7, 2006
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cellsAldo Maria Roccaro, Teru Hideshima, Noopur Raje, et al.Blood|October 24, 2002
Prognostic value of angiogenesis in solitary bone plasmacytomaShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.Proceedings of the National Academy of Sciences of the United States of America|December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaKlaus Podar, Giovanni Tonon, Martin Sattler, et al.Contemporary Clinical Trials Communications|August 5, 2022
A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncologyRahma Warsame, Joselle Cook, Briant Fruth, et al.American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trialPaul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.Ejhaem|July 18, 2022
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myelomaPaul G Richardson, Sundar Jagannath, Ajai Chari, et al.Blood|May 25, 2010
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complicationsGiada Bianchi, Robert A Kyle, Colin L Colby, et al.Pageof 80